NEW YORK (GenomeWeb) – The Alliance Global Group today announced an exclusive master agreement for the distribution of Invivoscribe Technologies' molecular diagnostics in Alliance's markets.

Based in San Diego, Invivoscribe's products include assays for detecting clonal gene rearrangements, gene translocations, and gene mutations in patients with suspected lymphoproliferations, among other things. It also has CLIA- and CAP-certified clinical reference laboratories in the European Union and the US to perform FLT2 and NPM1 mutation testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.